SPARC and colonic neoplasm: In colon cancer patients, SPARC mRNA expression in high-risk group also independently predicted short DSS (H=7,44; 95% CI [2,082-26,600], p=0,002) and short PFS (HR=1,83; 95% CI [1,021-3,302], p=0,042) (Supplementary Table S9).